Spatial immune biomarkers in triple-negative breast cancer: emerging evidence, technology trade-offs, and barriers to clinical translation.

Journal: Frontiers in immunology •

Abstract

Abstract text is not embedded in this discovery record. Please consult the full-text publication via the source link on the right.

Subjects & Keywords

How to Cite this Article

Zeng L, Lin W, Xue S, et al. (2026). "Spatial immune biomarkers in triple-negative breast cancer: emerging evidence, technology trade-offs, and barriers to clinical translation.". Frontiers in immunology. https://doi.org/10.3389/fimmu.2026.1899098